Analysis of coagulation alteration and its correlation with β2-microglobulin in 371 patients with newly diagnosed multiple myeloma

References

• Shen YJ, Mishima Y, Shi J, et al. Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 2021;137(17):2360–2372. doi:10.1182/blood.2020005885
   PubMed Web of Science ®Google Scholar
• Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004–2017: an observational study. J Hematol Oncol. 2019;12(1):22. doi:10.1186/s13045-019-0706-9
   PubMed Web of Science ®Google Scholar
• Velasco-Rodriguez D, Martinez-Alfonzo I, Velasco-Valdazo AE, et al. Enhanced thrombin generation detected with ST-genesia analyzer in patients with newly diagnosed multiple myeloma. J Thromb Thrombolysis. 2023;55(3):464–473. doi:10.1007/s11239-022-02765-8
   PubMed Web of Science ®Google Scholar
• Geng C, Yang G, Wang H, et al. The prognostic role of prothrombin time and activated partial thromboplastin time in patients with newly diagnosed multiple myeloma. Biomed Res Int. 2021;2021:6689457. doi:10.1155/2021/6689457
   PubMed Web of Science ®Google Scholar
• Al SA, Sidiqi MH, Muchtar E, et al. Prognostic role of beta-2 microglobulin in patients with light chain amyloidosis treated with autologous stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(8):1402–1405. doi:10.1016/j.bbmt.2020.04.024
   PubMed Web of Science ®Google Scholar
• Abdallah N, Baughn LB, Rajkumar SV, et al. Implications of MYC rearrangements in newly diagnosed multiple myeloma. Clin Cancer Res. 2020;26(24):6581–6588. doi:10.1158/1078-0432.CCR-20-2283
   PubMed Web of Science ®Google Scholar
• Chinese Hematology Association, Chinese Society of Hematology. The guidelines for the diagnosis and management of multiple myeloma in China (2022 revision). Chinese J Int Med. 2022;61(5):480–487.
   PubMedGoogle Scholar
• Charalampous C, Goel U, Kapoor P, et al. Thrombosis in multiple myeloma: risk estimation by induction regimen and association with overall survival. Am J Hematol. 2023;98(3):413–420. doi:10.1002/ajh.26806
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol. 2021;32(3):309–322. doi:10.1016/j.annonc.2020.11.014
   PubMed Web of Science ®Google Scholar
• Richard C, Cuadrado MA, Prieto M, et al. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol. 1990;35(2):114–117. doi:10.1002/ajh.2830350210
   PubMed Web of Science ®Google Scholar
• Baccouche H, Hadhri M, Aissi W, et al. The hypercoagulable state in multiple myeloma: the contribution of thrombin generation test. Int J Lab Hematol. 2019;41(5):684–690. doi:10.1111/ijlh.13093
   PubMed Web of Science ®Google Scholar
• Nielsen T, Kristensen SR, Gregersen H, et al. Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Thromb Res. 2021;202:108–118. doi:10.1016/j.thromres.2021.03.015
   PubMed Web of Science ®Google Scholar
• Fotiou D, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. Updates on thrombotic events associated with multiple myeloma. Expert Rev Hematol. 2019;12(5):355–365. doi:10.1080/17474086.2019.1604214
   PubMed Web of Science ®Google Scholar
• Schoen MW, Carson KR, Luo S, et al. Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb Haemost. 2020;4(7):1203–1210. doi:10.1002/rth2.12411
   PubMed Web of Science ®Google Scholar
• Hinterleitner C, Pecher AC, Kreisselmeier KP, et al. Disease progression and defects in primary hemostasis as major cause of bleeding in multiple myeloma. Eur J Haematol. 2020;104(1):26–35. doi:10.1111/ejh.13331
   PubMed Web of Science ®Google Scholar
• Zamagni E, Brioli A, Tacchetti P, et al. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. Semin Thromb Hemost. 2011;37(3):209–219. doi:10.1055/s-0031-1273085
   PubMed Web of Science ®Google Scholar
• Papageorgiou L, Alhaj HK, Thouroude S, et al. Modelization of blood-borne hypercoagulability in myeloma: a tissue-factor-bearing microparticle-driven process. TH Open. 2019;03(4):e340–e347. doi:10.1055/s-0039-1700885
   Google Scholar
• Guo L, Tong D, Yu M, et al. Phosphatidylserine-exposing cells contribute to the hypercoagulable state in patients with multiple myeloma. Int J Oncol. 2018;52(6):1981–1990.
   PubMed Web of Science ®Google Scholar
• Olah Z, Szarvas M, Bereczky Z, et al. Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant. Arch Pathol Lab Med. 2013;137(7):967–973. doi:10.5858/arpa.2012-0236-OA
   PubMed Web of Science ®Google Scholar
• Kotlin R, Sobotkova A, Riedel T, et al. Acquired dysfibrinogenemia secondary to multiple myeloma. Acta Haematol. 2008;120(2):75–81. doi:10.1159/000160182
   PubMed Web of Science ®Google Scholar
• Teng HW, Chen PM, Yang YH, et al. The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma. Jpn J Clin Oncol. 2007;37(8):609–614. doi:10.1093/jjco/hym074
   PubMed Web of Science ®Google Scholar
• Huang H, Li H, Li D. Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma. Blood Coagul Fibrinolysis. 2015;26(5):555–559. doi:10.1097/MBC.0000000000000296
   PubMed Web of Science ®Google Scholar
• Pandey S, Post SR, Alapat DV, et al. Prolonged prothrombin time correlates with serum monoclonal protein concentration in patients with plasma cell dyscrasia. Int J Lab Hematol. 2013;35(4):421–427. doi:10.1111/ijlh.12036
   PubMed Web of Science ®Google Scholar
• Kawashima I, Takano K, Kumagai T, et al. Combined coagulopathy can induce both hemorrhagic and thrombotic complications in multiple myeloma. Intern Med. 2018;57(22):3303–3306. doi:10.2169/internalmedicine.0915-18
   PubMed Web of Science ®Google Scholar
• Yin J, Zhu SS. Routine coagulation molecules predict nasopharyngeal carcinoma and associated metastases. Br J Biomed Sci. 2019;76(4):178–183. doi:10.1080/09674845.2019.1631943
   PubMed Web of Science ®Google Scholar
• Wakatsuki K, Matsumoto S, Migita K, et al. Preoperative plasma fibrinogen is associated with lymph node metastasis and predicts prognosis in resectable esophageal cancer. World J Surg. 2017;41(8):2068–2077. doi:10.1007/s00268-017-3991-x
   PubMed Web of Science ®Google Scholar
• Wang J, Liu H, Shao N, et al. The clinical significance of preoperative plasma fibrinogen level and platelet count in resectable esophageal squamous cell carcinoma. World J Surg Oncol. 2015;13:157. doi:10.1186/s12957-015-0543-4
   PubMed Web of Science ®Google Scholar
• Gogia A, Sikka M, Sharma S, et al. Hemostatic abnormalities in multiple myeloma patients. Asian Pac J Cancer Prev. 2018;19(1):127–130.
   PubMedGoogle Scholar